2003
DOI: 10.1002/cncr.11167
|View full text |Cite
|
Sign up to set email alerts
|

Second malignancies in children with neuroblastoma after combined treatment with 131I‐metaiodobenzylguanidine

Abstract: A novel approach is presented for the solution of production planning problems for multiproduct processes. A mixed‐integer programming (MIP) scheduling model is analyzed off‐line to obtain a convex approximation of feasible production levels and a convex underestimation of total production cost as a function of production levels. The two approximating functions are expressed via linear inequalities that involve only planning variables yet provide all the relevant scheduling information necessary to solve the p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
40
1
5

Year Published

2003
2003
2017
2017

Publication Types

Select...
8
1
1

Relationship

1
9

Authors

Journals

citations
Cited by 94 publications
(49 citation statements)
references
References 34 publications
3
40
1
5
Order By: Relevance
“…The incidence of secondary malignancy is similar to that observed in children treated with chemotherapy with a cumulative incidence of 7.6% and 14.3% at 5 and 10 y after therapy, respectively (103). Secondary malignancies including acute nonlymphoblastic leukemia, chronic myelomonocytic leukemia, angiomatoid malignant fibrous histiocytoma, malignant schwannoma, and rhabdomyosarcoma have been reported to occur at a median of 3 y (1-15 y) (104).…”
Section: Net Targeting For Therapy 123 I/ 131 I-mibg Theranostics Forsupporting
confidence: 67%
“…The incidence of secondary malignancy is similar to that observed in children treated with chemotherapy with a cumulative incidence of 7.6% and 14.3% at 5 and 10 y after therapy, respectively (103). Secondary malignancies including acute nonlymphoblastic leukemia, chronic myelomonocytic leukemia, angiomatoid malignant fibrous histiocytoma, malignant schwannoma, and rhabdomyosarcoma have been reported to occur at a median of 3 y (1-15 y) (104).…”
Section: Net Targeting For Therapy 123 I/ 131 I-mibg Theranostics Forsupporting
confidence: 67%
“…3,8,25,26 Treatment may involve alkylating agents, topoisomerase II inhibitors, (131)I-metaiodobenzylguanidine [(131)I-MIBG], platinums and/or radiation, that have been associated with an increased risk of secondary leukemias, bone marrow disorders, and solid tumors (breast cancer and thyroid cancer), and more recently, bone marrow transplantation, which has been associated to an increased risk of secondary solid tumors. 26 Second malignant neoplasms of the kidney and digestive organs have also been observed.…”
Section: Epidemiologymentioning
confidence: 99%
“…External-beam radiation therapy (EBRT) proved effective in small series of localized neuroblastoma [7] and infants' neuroblastoma [24] but data in high-risk neuroblastoma are still limited [5,13,19]. Radiation can cause long-term effects like scoliosis, soft-tissue hypoplasia, hypothyroidism, and secondary malignant disease [1,11,14,21,23,24,26,30] and should, therefore, be applied only when clearly indicated.…”
Section: Introductionmentioning
confidence: 99%